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Abstract
Background: Use of a reliable contraception method has become an inclusion criterion in prevention trials to
minimize time off product. We report on hormonal contraceptive prevalence, uptake, sustained use and correlates
of use in the Microbicides Development Programme (MDP 301) trial at the Masaka Centre in Uganda.
Methods: HIV negative women in sero-discordant relationships were enrolled and followed-up for 52 to 104 weeks
from 2005 to 2009. Contraceptive use data was collected through self-report at baseline and dispensing records
during follow-up. Hormonal contraceptives were promoted and provided to women that were not using a reliable
method at enrolment. Baseline contraceptive prevalence, uptake and sustained use were calculated. Uptake was
defined as a participant who reported not using a reliable method at enrolment and started using a hormonal
method at any time after. Logistic regression models were fitted to investigate predictors of hormonal
contraceptive uptake.
Results: A total of 840 women were enrolled of whom 21 aged ≥50 years and 12 without follow-up data were
excluded; leaving 807 (median age 31 IQR 26–38) in this analysis. At baseline, 228 (28%) reported using a reliable
contraceptive; 197 hormonal, 28 female-sterilisation, two IUCD and one hysterectomy. As such 579 were not using
a reliable contraceptive at enrolment, of whom 296 (51%) subsequently started using a hormonal contraceptive
method; 253 DMPA, four oral pills, and two norplant. Overall 193 (98%) existing users and 262 (88%) new users
sustained use throughout follow-up. Independent correlates of hormonal contraceptive uptake were: younger
women ≤30 years, aOR = 2.5, 95% CI: 1.7–3.6 and reporting not using contraceptives at baseline due to lack of
access or money, breastfeeding or other reasons, in comparison to women who reported using unreliable method.
Conclusion: Promotion and provision of hormonal contraception doubled the proportion of women using a
reliable method of contraception. Uptake was pronounced among younger women and those not previously using
a reliable method because of lack of access or money, and breastfeeding. Promotion and provision of hormonal
contraceptives in trials that require the interruption or discontinuation of investigational products during pregnancy
is important to reduce the time off product.
Trial registration: Protocol Number ISRCTN64716212.
Keywords: Hormonal contraceptives, Contraceptive uptake, Microbicides, Clinical trials
* Correspondence: Andrew.Abaasa@mrcuganda.org;
andrew.abaasa@yahoo.com
1MRC/UVRI Uganda Research Unit on AIDS, P.O Box 49, Entebbe, Uganda
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Abaasa et al. Reproductive Health  (2017) 14:36 
DOI 10.1186/s12978-017-0296-3
Plain English Summary
The use of reliable contraceptives is increasingly being
added as an inclusion criterion in HIV prevention trials.
Studies have not reported on the uptake of reliable con-
traceptives after enrolment among women participating
in large phase III microbicide clinical trials to inform fu-
ture trials. In this article we determined uptake of hor-
monal contraceptives and its correlates in a phase III
vaginal microbicide trial.
Hormonal contraceptives (pill, injectable Depot
medroxyprogesterone acetate (DMPA) and Norplant or
intrauterine contraceptive device (IUCD)) were promoted
and provided to women that were not using a reliable
method at enrolment into the trial and during follow up.
Data on 807 women were analysed and 579 were not
using a reliable contraceptive method at enrolment, of
which 296 started using a hormonal contraceptive
method mainly DMPA (253).
Promotion and provision of hormonal contraceptives
substantially improved uptake of these methods. The up-
take was particularly highest among younger women
and among women who couldn’t or didn’t think they
needed to access contraceptives. This evidence highlights
the benefit of promoting and providing hormonal con-
traceptives to trial participants where pregnancy could
disrupt the use of investigational products.
Background
In 2014 it was estimated that only 28% [1] of women in
Africa and 17% [2] in Sub-Saharan Africa were using
modern methods of contraception (injectable, norplant,
intrauterine contraceptive device (IUCD), pill, dia-
phragm, male condom and sterilization). In Uganda,
modern contraceptive use among women of reproduct-
ive age increased from 18% in 2006 [3] to 32% in 2011
[4]. The proportion using modern methods is lower than
that reported in neighbouring Kenya (39%) and Rwanda
(45%), similar to Tanzania (26%) but higher than
Burundi (18%) in 2011 [5]. Generally, the use of modern
contraceptives in Uganda is lower among women aged
25 years or less (20%), married (26%), or those living in
rural areas (23%) [3] [6]. The unmet need for any con-
traceptives in Uganda remains high at 41% especially
among women who are currently married, living in rural
areas and living in the Northern region [7]. In 2011, the
total fertility rate among women of reproductive age in
Uganda was estimated to be 6.2 and as a consequence
the country’s population is expected to double over the
next 20 years [5]. Addressing the unmet contraceptive
needs of Ugandan women is critical for couples to limit
or space births [8].
In addition, the need for female initiated and con-
trolled HIV preventive options remains high. In 2011,
the HIV prevalence among women of reproductive age
in Uganda was 8% [9] and incidence of approximately
1% [10]. Contraceptive use among sero-discordant cou-
ples is low 23% [11] and similar to the national average
among married women in general [12]. Similarly, con-
dom use among sero-discordant couples is equally low
(36%) [11]. Dual contraceptive use (condoms plus a
modern contraceptive) among HIV positive women of
reproductive age attending urban clinics is not good ei-
ther 12%, with 42% of HIV-positive pregnant women
reporting their pregnancy to be unintended [13]. Overall,
condom use with a spouse or partner is low among men
(6%) and women (4%) [14]. However, condom use while
having sex with causal sexual partners has increased and
it is still more likely among men than women [14].
A number of clinical trials evaluating new HIV preven-
tion technologies including vaginal microbicides and oral
pre-exposure prophylaxis (PrEP) have been conducted in
Uganda [15–19]. These trials are powered to provide suffi-
cient sample sizes to assess the efficacy of investigational
products. Given the unknown effects of the investigational
products on the unborn foetus, product use is usually
interrupted or discontinued during pregnancy. A higher
than anticipated pregnancy incidence may affect the statis-
tical power of a trial to detect the efficacy of a product.
Limiting the risk of unintended pregnancies in clinical tri-
als by supporting women’s use of reliable contraceptives
(injectable, norplant, pill, IUCD and female sterilisation)
helps to avoid a loss of statistical power. The use of reli-
able contraceptives is increasingly being added as an in-
clusion criterion in HIV prevention trials [20]. The use of
contraceptives at time of enrolment in later stage microbi-
cide clinical trials has ranged from 10% in Nigeria [21] to
56% in Uganda [15] and South Africa [22]. The baseline
use of hormonal (injectable, norplant and pills) contracep-
tives has ranged from 9% in Nigeria [21] to 15% in Ghana
[23]. To date, studies have not reported on the uptake of
reliable contraceptives after enrolment among women
participating in large phase III microbicide clinical trials.
Microbicide trials enrol women who are not intending to
get pregnant during the course of the trial, yet pregnancy
rates in efficacy trials have ranged from 1 to 27 per 100
women-years [24].
In this analysis we report on the baseline contraceptive
use, correlates of hormonal contraceptive uptake after
enrolment, and the sustained use of hormonal contra-
ceptives during follow-up among women in sero-
discordant couple sexual relationship enrolled in the
Microbicides Development Programme (MDP 301) clin-
ical trial in South-Western Uganda.
Methods
MDP301 was an international, randomized, double-
blind, placebo-controlled parallel-group phase III clinical
trial, designed to evaluate the safety and efficacy of 0.5%
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and 2% PRO2000 candidate microbicide gels in prevent-
ing vaginally acquired HIV-1 infection. The trial design
and trial results have been reported elsewhere [15, 25,
26]. In summary, participants were enrolled at 13 clinics
across six research centres, three in South Africa and
one each in Tanzania, Uganda and Zambia. This analysis
is based on MDP301 data collected exclusively at the
Masaka clinic research centre in South-Western Uganda.
The MDP301 Masaka clinical trial centre enrolled HIV-
negative healthy women in a known HIV sero-discordant
relationship and followed them for a minimum of 52 weeks
and a maximum of 104 weeks. Women in sero-discordant
relationships were identified and enrolled following a
sero-survey conducted between September 2005 and
August 2008. Follow-up continued until September 2009.
The eligibility criteria are in Table 1.
Details of the clinical, laboratory and pharmacy proce-
dures, data management, field activities, counselling
package and follow-up schedules are described elsewhere
[15, 25–27]. Women were randomised to one of the
three gel groups; 0.5% PRO2000, 2% PRO2000 or pla-
cebo. Screening visits occurred no more than 6 weeks
prior to enrolment, and follow-up visits were scheduled
every four weeks after enrolment and conducted at ei-
ther the research clinic or designated government health
centres. At screening, data were collected on demo-
graphic and behavioural characteristics. The following
variables were considered in this analysis: age, religion,
education level, employment status, method of contra-
ceptives used and reason for non-use. Behavioural data
were collected at the four weekly follow-up visits, in-
cluding data on gel and condom use at the last sex act.
Extended behavioural data were collected at the longer
clinical examination visits, which occurred at weeks 4,
12, 24, 40, 52, 64, 76, 88, 100 and 104 after enrolment.
Contraceptive use data were collected at every visit.
Women were asked whether they were using any contra-
ceptive method, if they were, a single method was cap-
tured which could include unreliable methods such as
condoms, the rhythm method, withdrawal or traditional
remedies. If they reported not using a contraceptive
method, a single reason for none-use was captured which
could include wanting to become pregnant, the partner
being sterilised, or currently breastfeeding (locally consid-
ered a period of infertility). However, women who re-
ported using an unreliable method were not asked why
they were not using a reliable method.
The research team offered contraceptive services at
every visit, which included the provision of the oral
contraceptive pill and injectable Depot medroxyproges-
terone acetate (DMPA). The study clinic referred women
who chose to use the norplant or intrauterine contracep-
tive device (IUCD) to the Marie Stopes clinic located
about one km from the study clinic. Women were given
contraceptive cards, which captured the woman’s contra-
ceptive use history and future prescription renewal dates.
They were asked to bring their contraceptive cards at
every visit. At each four-weekly follow-up visit we con-
ducted rapid urine pregnancy tests and interrupted gel if
the woman tested positive for pregnancy. The study pro-
vided transport expenses to and from the study clinic.
Enrolled women ranged in age from 16 to 59 years
old. Only women of reproductive age between 16 and 49
years were included in this analysis. We further excluded
women that did not have any follow-up data. We de-
fined reliable contraceptives as non-barrier methods
likely to significantly reduce the risk of pregnancy and
categorised the following contraceptive methods as reli-
able: female sterilisation, pill, DMPA, Norplant and
IUCD. We included the one woman who had had a hys-
terectomy in the group defined as using reliable contra-
ceptive methods. We categorised condoms, the rhythm
method, withdrawal, traditional remedies, breastfeeding
or no method as ‘not reliable’. We did not classify con-
dom use as a reliable method of contraception because
in this community only male condom is readily and
freely available and its use is largely male controlled.
Women who were not using a reliable contraceptive at
Table 1 MDP 301 Uganda: eligibility criteria
Eligible Ineligible
• Sexually active
• 16 years old or above
• HIV-negative at screening
• Willing to undergo regular HIV testing and receive the result
before randomisation
• Willing to undergo regular speculum examinations and genital
infection screens
• Willing to have regular urine pregnancy tests
• Willing to use study gel as instructed
• Willing to receive health education about condoms
• Willing and able to give informed consent
• Unable or unwilling to provide a reliable method of contact for the field team
• Likely to move permanently out of the area within the next year
• Likely to have sex more than 14 times a week on a regular basis during the
course of follow-up
• Using spermicides regularly
• Pregnant or within 6 weeks postpartum at enrolment
• Had a severe clinical or laboratory abnormality
• Requiring referral for assessment of a clinically suspicious cervical lesion
• Had treatment to the cervix, or to the womb through the cervix, within 30 days
of enrolment
• Had known latex allergy
• Participating, or having participated within 30 days of enrolment, in a clinical trial
of an unlicensed product, microbicide, barrier method or any other intervention
likely to impact on the outcome of this trial
● Considered unlikely to be able to comply with the protocol
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baseline were encouraged to use hormonal methods
(pill, DMPA, or Norplant). We categorised ‘new’ hormo-
nal contraceptive users as any women who reported not
using a reliable contraceptive method at the enrolment
visit and reported using a hormonal method during at
least one follow-up visit.
Statistical methods
The analysis was separated into three parts, first compar-
ing women who reported using a reliable contraceptive
method at enrolment to women who reported not using a
reliable method. Secondly, women who started using a
hormonal method after enrolment (new users) were com-
pared to those that did not switch to a hormonal method
(non-adopters) during the trial. Lastly, hormonal users
that sustained use of the initial method overtime were
compared to those that switched between hormonal
methods after initiation. We defined sustained use of a
hormonal method as a woman taking up a hormonal
method and using it throughout the study follow up
period.
Descriptive statistics were used to summarise women’s
characteristics. The proportion of women using hormonal
contraceptive was estimated as the number using hormo-
nal contraceptives divided by the number of women at-
tending the visit. We examined associations between
women using reliable and those not using reliable contra-
ceptives at baseline, and between women who started and
sustained use of a hormonal method to those that
switched between hormonal methods using chi-square.
The associations between new hormonal contraceptive
users and non-adopters during follow up were assessed
using odds ratios, with 95% confidence intervals (CI), and
by fitting logistic regression models. Only factors for
which the association attained a statistical significance at
the 15% [28] level using a likelihood ratio test (LRT) in a
univariable analysis were considered for the multivariable
model. In the multivariable model, factors were removed
from the model using a backward elimination algorithm if
removing the term did not make the fit of the model
significantly worse at the 5% level on a likelihood ratio test
(LRT). All analyses were conducted using Stata 11
(StataCorp, College Station, Texas, USA).
Results
A total of 1,161 women were screened and 840 (72.4%)
enrolled in Uganda. The main reasons for ineligibility
were HIV-positive status (111), pregnancy (51), not be-
ing sexually active (18), clinical findings making enrol-
ment inadvisable (5), being unlikely to comply with the
protocol (4) or likely to have sex more than 14 times per
week (1) Fig. 1. An additional 131 women were eligible
at screening but chose not to enrol in the study. Of the
840 women enrolled, 33 were excluded from this
analysis, 21 women aged 50 or above and 12 women that
did not have any follow up data. This left 807 women
for analysis. The median age of women included in the
analyses was 31 years (inter-quartile range IQR: 26–38).
Contraceptive use at baseline
At baseline, 228 women (28.2%) reported using a reliable
contraceptive method. A further 245 women (30.4%) re-
ported using an unreliable contraceptive method, mainly
condoms (215), the natural rhythm method (15), trad-
itional oral methods (14) and withdrawal (1); 334 women
(41.4%) reported not using any method of contraception.
Of the 228 women using a reliable contraceptive
method, 197 (24.4% of the 807 women) reported using
hormonal contraceptives (161 using DMPA, 33 using the
oral pill and 3 using Norplant), 28 (3.5%) were sterilised,
two (0.2%) were using the IUCD, and one (0.1%) had
had a total hysterectomy. The only factor significantly
associated with use of a reliable contraceptive method at
enrolment was employment status with women who
were in full time employment or who were housewives
being more likely to use reliable contraception than un-
employed women (Table 2).
Table 2 Baseline characteristics of reliable contraceptive users
Characteristic N (col %) Using a reliable
contraceptive
n (row %)
P-value
All participants 807 228 (39.4)
Median age years (IQR) 31 (26-38) 30 (25-36) 0.106
Age group(years)
31+ 415 (51.4) 104 (25.1) 0.106
25-30 240 (29.8) 74 (30.8)
16 – 24 152 (18.8) 50 (32.9)
Religion
Christians 701 (86.9) 200 (28.5) 0.652
Muslim 106 (13.1) 28 (26.4)
Level of education
None 117 (14.5) 26 (22.2) 0.258
Primary 548 (67.9) 158 (28.8)
Secondary+ 142 (17.6) 44 (31.0)
Employment status
Employed full time 99 (12.3) 36 (36.4) 0.025
Unemployed 592 (73.3) 152 (25.7)
House wife 116 (14.4) 40 (34.5)
Condom use at the last sex act in the last 4 weeks prior to enrolment
No 240 (29.7) 70 (29.2) 0.725
Yes 508 (63.0) 144 (28.3)
Did not have sex 59 (7.3) 14 (23.7)
Col %); Column percentage
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Uptake of hormonal contraceptives
Table 3 presents the characteristics of the 579 women
who were not using a reliable method of contraception
at baseline. The median age was 31 (IQR: 26–38) with
51.4% being more than 30 years old. The majority were
Christian (86.9%), had attained only primary education
(67.9%) and were unemployed (73.3%).
As shown in Table 3, 296 (51.1%) women were defined
as ‘new’ hormonal contraceptive users in terms of not
using a reliable method at baseline and reporting use of
a hormonal method during at least one follow-up visit.
Of the new hormonal contraceptive users, 253 (85.5%)
women started using DMPA, 41 (13.9%) oral pill and
two (<1%) norplant. About two-thirds of new hormonal
contraceptive users had reported not using any contra-
ceptive method at enrolment (204; 68.9%), and the re-
mainder had either switched from or supplemented
condom use (85; 28.7%) or reported using another
unreliable method (7; 2.4%). Figure 2 shows the propor-
tion of women reporting hormonal contraceptive use at
each of the extended behavioural visits throughout the
trial. The graph illustrates that the majority of new hor-
monal contraceptive users started use within the first
three months of follow-up and that hormonal contracep-
tive use was consistently over 50% from the six-month
visit onwards.
Of the 283 women who did not start using a hormonal
method of contraception, 8 opted for other reliable
methods such as sterilisation (5) and the IUCD (3), while
250 women continued to report unreliable contraceptive
methods such as condoms (242), and the natural rhythm
method or withdrawal (8). Only twenty-five women
never reported using any contraceptive method.
At enrolment, only 144 of the 807 (17.8%) women
who had had sex in the previous 4 weeks reported dual
use of a condom and a reliable contraceptive method at
Table 3 Factors associated with uptake of hormonal contraceptive methods in multivariable model
Characteristic N (col %) Up take of Hormonal
contraceptives n (row %)
uOR (95% CI) LRT P-value aOR (95% CI)
All participants 579 296 (51.1)
Age group in years
31+ 311 (53.7) 116/311 (37.3) 1 <0.001 1
16 – 30 268 (46.3) 180/268 (67.2) 3.3 (2.4-4.7) 2.5 (1.7-3.6)
Religion*
Christians 503 (86.9) 251/503 (49.9) 1 0.122
Muslim 76 (13.1) 45/76 (59.2) 1.5 (0.9-2.4)
Level of education
None 92 (15.9) 43/92 (46.7) 1 0.747
Primary 390 (67.4) 204/390 (52.3) 1.2 (0.8-1.9)
Secondary+ 97 (16.7) 49/97 (50.5) 1.1 (0.6-2.0)
Employment status
Employed full time 62 (10.7) 26/62 (41.9) 1 0.150
Unemployed 440 (76.0) 225/440 (51.1) 1.5 (0.9-2.6)
House wife 77 (13.3) 45/77 (58.4) 1.8 (0.9-3.5)
Contraceptive method at enrolment
Condom 215 (37.1) 85/215 (39.5) 1 <0.001
No method 334 (57.7) 204/334 (61.1) 2.4 (1.7-3.4)
Other 30 (5.2) 7/30 (23.3) 0.5 (0.2-1.3)
Unreliable method of family planning used at baseline/reasons for non-use
Use of unreliable method 245 (42.3) 92/245 (337.6) 1 <0.001 1
Breast feeding 141 (24.4) 111/141 (78.7) 6.0 (3.7-9.7) 5.0 (3.1-8.1)
Spent ≥2 years without getting pregnant 77 (13.3) 20/77 (26.0) 0.6 (0.3-1.1) 0.7 (0.4-1.2)
Side effects/fear 60 (10.4) 30/60 (50.0) 1.5 (0.9-2.6) 1.4 (0.8-2.4)
No access/money 31 (5.4) 25/31 (80.6) 7.2 (2.9-18.3) 6.8 (2.6-17.4)
Other 25 (4.3) 18/25 (72.0) 4.5 (1.8-11.1) 4.2 (1.7-10.7)
uOR unadjusted odds ratio, CI confidence interval, LRT likelihood ratio test, aOR adjusted odds ratio: factors adjusted for age, reasons for non-contraceptives use
prior to enrolment, contraceptive use status at baseline, employment status and religion
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their last sex act. Of the 579 non-hormonal contracep-
tive users at baseline, 367 (63.4%) reported using a con-
dom at their last sex act. Of the 296 new hormonal
contraceptive users, 208 (70.3%) reported the use of a
condom at the last sex act at every visit compared to
221/283 (78.1%) among the women who did not start
using hormonal contraceptives.
Among women who reported not using any contracep-
tive method at enrolment, the main reasons included
141 (42.2%) reporting they were currently breast-feeding
(perceived locally to prevent conception), 77 (23.0%) as-
sumed they were infertile after at least 2 years of not
conceiving, 60 (18.0%) had previous experience of side
effects or a fear of using contraceptives, 31 (9.3%) re-
ported lack of access or money for contraceptives, as
well as 25 (7.5%) women reporting other reasons such as
partner opposition or refusal, getting tired of using con-
traceptives and their partner wanting a child.
Fig. 1 Masaka Centre study profile
Fig. 2 Proportion of women reporting use of hormonal contraception
over time
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As shown in Table 3, factors that were significantly asso-
ciated with hormonal contraceptive uptake at the 15% level
in univariable analysis included age, religion, employment
status, reported unreliable method of family planning at
baseline, and reasons for not using a reliable method of
contraception at baseline. After controlling for all factors in
multivariable analysis, younger women (≤30 years) were
more than twice as likely to have started using hormonal
contraceptives, than older women (>30). Women were also
significantly more likely to start using hormonal contracep-
tives if they had reported not using contraceptives at base-
line due to a lack of access or money, breastfeeding or
other reasons, compared to those who reported the use of
other unreliable contraceptive methods.
Sustained hormonal contraceptive use
Of the 296 new hormonal contraceptive users, 262
(88.5%) sustained use of the new hormonal method
throughout the remainder of their follow-up. Most
women reported use of hormonal methods for a median
of 6 times (IQR 4–7) after initiation until end of follow-
up. The remaining 34 (11.5%) switched between hormonal
methods, with 29 starting on DMPA but switching to the
oral pill, four starting on DMPA and switching to Nor-
plant, and one starting with the oral pill and switching to
Norplant. Women indicated bleeding as the main reason
for switching from DMPA. After initiating hormonal
contraceptive use, none of the 296 new contraceptive
users reported not using hormonal contraceptives at a
subsequent visit up to the end of their follow-up. There
were no statistically significant differences between
women who sustained the initial hormonal contraceptive
method and those that switched methods in terms of age,
religion, employment status or educational level (data not
shown). Of the 197 women already using hormonal con-
traceptives at baseline, 193 (98.0%) sustained use of a hor-
monal method throughout follow-up.
Discussion
In this study, we assessed contraceptive prevalence, up-
take and sustained use among women enrolled in an
HIV prevention trial in Masaka, who were in sero-
discordant relationships. The baseline prevalence of
reliable contraceptive use was low and similar to the na-
tional 2011 average among women of reproductive age
in Uganda [3]. The specific use of hormonal contracep-
tives at baseline in this cohort was similar to the overall
rate in the central region of Uganda [3] where the study
was conducted. Contraceptive prevalence is consistently
higher in Central and Western regions of Uganda [3] in
comparison to the Northern and Eastern regions. A
number of factors have been previously advanced for
geographical variations in contraceptive use prevalence
including community level cultural beliefs (such as value
attached to children), the presence and quality of repro-
ductive health services and accessibility in terms of
transport routes [29]. The Northern and Eastern regions
of Uganda were affected by a civil war for over two de-
cades and this contributed to the breakdown of social
services and community coping mechanisms [29].
In this study, the majority of women reporting reliable
contraceptive use at baseline used DMPA, which is con-
sistent with both national data and data from the central
region of Uganda [3]. It was encouraging that contracep-
tive prevalence did not differ by age, educational status or
religion. Nationally both younger age and lower educa-
tional status are associated with lower contraceptive use
[3]. In this cohort unemployed women were significantly
less likely to use contraceptives at baseline. In the national
data, employment status is not reported yet women in the
lowest wealth quintile had the lowest contraceptive preva-
lence [3], which is likely to explain the association ob-
served with unemployment in our study.
The most striking finding from this study was that over
half of all women who were not using reliable contracep-
tives at baseline started using hormonal contraceptives,
mainly within the initial three months of the study.
Uptake was significantly higher among younger women.
Although our results do not suggest a significant age
differentiation between women’s use of contraceptives at
baseline, the uptake data suggests a substantial unmet
need among this younger age group. The reasons that
women reported for not using a reliable method of contra-
ception at baseline were independently associated with
hormonal contraceptives uptake. Women who reported a
lack of access or a lack of money as being the main reason
for non-use were over six times more likely to initiate hor-
monal contraceptive use than women using an unreliable
method at baseline. Although contraceptives are freely
available in Uganda, distance from health centres has been
documented as a structural barrier to health services in
Sub-Saharan Africa, including Uganda [30, 31]. This asso-
ciation between lack of access and low usage has been
observed elsewhere in Uganda and Kenya [32, 33]. This
finding, along with the correlation of lower use among
unemployed women, highlights the need for either finan-
cial support for lower income women to be able to travel
to existing health centres or for the expanded provision of
more accessible family planning services.
In Uganda, and elsewhere, it is often believed that
women cannot conceive when breastfeeding. Women
who reported not using contraceptives at baseline due to
breastfeeding were five-times more likely to initiate use
during the study. This association has been observed in
other parts of Africa [34] and highlights the need to dis-
seminate accurate information about contraception and
the need for better contraceptive messages and provision
in ante-natal care settings [35].
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Other reasons for non-contraceptive use reported at
baseline such as partner opposition or refusal, women get-
ting tired of using contraceptives and partners wanting a
child, were also associated with high uptake of hormonal
contraceptives during follow-up, although the numbers
were low. In the Masaka centre we enrolled couples to-
gether and regularly provided couple counselling. Evi-
dence from this centre suggests that generally couples
jointly decided on use of the trial gel and women reported
feeling supported by their partners to use the gel [36].
This evidence suggests that joint decision making or part-
ner support could be an influencing factor in improving
usage of hormonal contraceptives as well as gel.
It was encouraging to see very high levels of sustained
use of hormonal methods among both women who re-
ported using them at baseline and among new users.
Uptake and sustained use was high in this cohort, and
given the baseline contraceptive prevalence was similar
to the local prevalence, it is likely that the study clinic
filled a gap of provision in this community. However it
is also likely that participation in the trial specifically
motivated women to start and continue to use contra-
ceptives. There is limited evidence on adherence and
reasons for interruption and discontinuation, and further
qualitative research is needed to help support appropri-
ate uptake and sustained use in health care settings.
This study highlights the importance of offering hor-
monal contraceptives as a standard of care in clinical tri-
als in order to reduce the risk of pregnancies requiring
time off investigational product. This benefit has been
illustrated in other HIV prevention trials as well [23, 37]
However, there are concerns about the association
between the use of hormonal contraceptives and an in-
creased risk of HIV as observed in some studies [38–42]
but not others [43–46]. Currently, the risks of withdraw-
ing hormonal contraceptives outweigh the benefits in re-
lation to increased risk of unwanted pregnancies and
pregnancy complications [47–50]. The World Health
Organisation has recommended continued use of hor-
monal methods until conclusive evidence of risk is avail-
able, with increased counselling for dual protection with
condoms [51].
It was concerning to note that dual use of condoms
and a reliable contraceptive method was very low at
baseline among this cohort of HIV-negative women in
sero-discordant relationships reportedly not wanting to
get pregnant. However, baseline condom use for HIV
prevention at the last sex act was high at 63%. Of par-
ticular importance is the fact that the increased uptake
of hormonal contraception did not negatively impact on
condom use, demonstrating the potential to improve
dual method use. More effort is needed to promote dual
contraceptive use especially in light of the World Health
Organization (WHO) guidelines [51] recommending
condom use along with hormonal methods to prevent
possible increased risk of HIV acquisition.
Some of the limitations of this analysis are; we did
not collect data on marital status, partner attitudes to
contraceptive use, parity and area of residence all of
which have been associated with contraceptive prefer-
ence and use [3, 51, 52]. Furthermore, we did not
collect data on the reasons for non-contraceptive use
during follow up amidst free provision of contracep-
tives. Collection of such data could help inform future
strategies aimed at improving contraceptive use during
follow up.
The major strength of this study is that we assessed
uptake in a study that provided contraceptives and
where women were counselled on both the use and im-
portance of adherence to dual contraceptive use. The
contraceptive use data were collected by two independ-
ent investigators and cross checked at each visit.
Conclusion
In a study with baseline contraceptive use similar to the
general population, we saw a substantial uptake of hor-
monal contraceptives. The uptake of hormonal contra-
ceptives did not displace the high use of condoms
among sero-discordant couples, demonstrating the po-
tential to improve the use of dual methods. The uptake
was particularly pronounced among younger women
and among women who couldn’t or didn’t think they
needed to access contraceptives. The rate of sustained
use was exceptionally high in a study with up to two
years follow-up. This evidence highlights the benefit of
promoting and providing hormonal contraceptives to
trial participants where pregnancy could disrupt the use
of investigational products. While contraceptive use has
improved in Uganda, only a quarter of women of repro-
ductive age report usage, unmet need remains high and
dual method use low. As such this study also highlights
the opportunities by which health care providers could
fill gaps in provision including expanding access to low
income and younger women, and enhancing accurate
contraceptive messaging.
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